Bringing Health Home: Evaluation of a Residential-based Telehealth Care Coordination Intervention
概览
- 阶段
- 不适用
- 干预措施
- Usual Care
- 疾病 / 适应症
- Mental Disorders, Severe
- 发起方
- University of Maryland, Baltimore
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Change in Health Service Costs
- 状态
- 进行中（未招募）
- 最后更新
- 2个月前
概览
简要总结
Individuals suffering from Serious Mental Illnesses (SMI) are at risk for serious adverse health and social outcomes compared to the general population due to a high prevalence of chronic physical health disorders such as cardiovascular disease, hypertension, and Type II Diabetes, along with consequences of mental distress such as suicide, substance abuse, and acute stress.While pharmacological treatments exist for these conditions, they have limited effectiveness in SMI populations because: (1) up to 60% of individuals with SMI do not take their psychiatric or somatic medications as prescribed, (2) individuals with SMI have poorer clinical outcomes and experience high rates of hospitalizations, and (3) individuals with SMI experience worse care. Challenges in the management of these complex chronic health and mental health conditions have led to the development of intensive community-based service delivery programs. However, as currently structured these intensive in-person interventions have only had limited impact optimizing service delivery, and consequently on adherence to treatment and health outcomes. While in-person clinical contact in select situations is important, telehealth may serve as an effective and nimble intervention to help meet the high need for clinical intervention for SMI populations and particularly those with geographically limited-service access. Although research exists regarding the efficacy of telehealth with SMI populations, most of the existing interventions with this population have been designed for institutional settings, not community settings, because of barriers to adoption of telehealth such as limited access to digital technology, technical support difficulties and cost of necessary technology. The COVID-19 pandemic has underscored the need for developing effective telemedicine and telemonitoring technologies to serve the unique needs of this vulnerable population in community settings. This project builds on a successful Phase I SBIR project and ongoing Phase II clinical trial of the Medherent medication management platform. This study will test an expanded set of telehealth care-coordination services that can be used to address the broad health needs of individuals diagnosed with SMI living in community settings and supported by community mental health agencies. The study team will recruit 300 individuals, including 200 individuals currently using the device and 100 new users of the device. The study will test the existing Medherent platform and a set of extended services. Our key outcomes include acute service use, receipt of preventive and other health screenings, health outcomes and costs of services. The study will use a Stepped Wedge Design approach with a matched comparison group to identify potential benefits of the intervention.
研究者
George Unick
Associate Professor
University of Maryland, Baltimore
入排标准
入选标准
- •Serious Mental Illness Diagnosis
- •Prescribed psychiatric medications
- •18 to 80 years old
- •Receives services by a participating community mental health agency at time of enrollment
- •Be unable to consent to the study as assessed by the consent questionnaire.
- •Sample 1: Current Users of Medherent or
- •Sample 2: Willing or able to authorize to have the Medherent device in your residence
排除标准
- •Unable to have the Medherent device in residence
研究组 & 干预措施
Usual Care
Usual Care: no intervention elements.
Existing Medherent
Group using the Medherent Device with no added intervention components.
干预措施: Medherent
New Medherent
Group using Medherent Device with added interventional components.
干预措施: Medherent
结局指标
主要结局
Change in Health Service Costs
时间窗: Two years prior to study enrollment to at least one year after study enrollment.
Costs of health services and mental health agency care will be calculated from Medicaid Claims data. These costs will be calculated for outpatient care, emergency room/urgent care, and inpatient hospitalization care by summing up all the costs of medical claims in each of these categories by month.
Health Service Utilization
时间窗: Two years prior to study enrollment to at least one year after study enrollment.
The study team will use medical records and claims data to calculate monthly counts of outpatient/ambulatory care events, inpatient hospitalization, and Emergency Room or urgent care visits. The Healthcare Effectiveness Data and Information Set (HEDIS) tool will be used to identify preventable hospitalization or emergency room visits, follow up care after hospitalizations or emergency room visits.
Consumer Satisfaction STAR-P
时间窗: Change from Baseline to 6 months to 12 Months
Consumers self reports of services satisfaction with agency services. Scale is between 12 and 60. Higher scores are associated with higher satisfaction with services.
Reported Low-density lipoprotein (LDL)/High-density lipoprotein (HDL)
时间窗: Two years prior to study enrollment to at least one year after study enrollment.
Reported Low-density lipoprotein (LDL)/High-density lipoprotein (HDL) will be use to assess adherence to medication by modeling individual change change over time. Normal HDL is 45 to 70 mg/dL for men and 50 to 90 mg/dL for women. The cutoff for good total cholesterol to HDL ratio is 5:1. Lower ratios are better than higher ratios.
Diabetes control as reported hemoglobin A1c levels
时间窗: Two years prior to study enrollment to at least one year after study enrollment.
Reported hemoglobin A1c will be use to assess adherence to medication by modeling individual change change over time. A1C levels between 5.7 and less than 6.5% will be conferred as prediabetes range. A1C level of 6.5% or higher are considered in the diabetes range.
High blood pressure.
时间窗: Two years prior to study enrollment to at least one year after study enrollment.
Reported blood pressure will be use to assess adherence to medication by modeling individual change change over time. Scores will be considered normal if systolic is less than 120 mm Hg and diastolic less than 80 mm Hg. Scores will be considered elevated if systolic is 120-129 mm Hg and diastolic is less than 80 mm Hg. Scores will be considered evidence of hypertension if systolic is greater than 130 mm Hg and diastolic is more than 80 mm Hg.